Phase 3 N=688 Phase 3 Papulopustular Rosacea Study
Papulopustular Rosacea
Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=683 Phase 3 Papulopustular Rosacea Study
Papulopustular Rosacea (PPR)
Primary: Success Rate — 38.4; 11.6 Percentage of participants — p=<0.001
Phase 4 N=30 Photodynamic Therapy for Papulopustular Rosacea
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
Phase 2 N=10 Open Label Pilot Study of Apremilast in Treatment of Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98
Phase 2 N=216 Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Papulopustular Rosacea
Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)
Phase 3 N=962 CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Papulopustular Rosacea
Primary: Percent Change in Inflammatory Lesions From Baseline to Week 16 — -83; -73.7 percentage of change
Phase 2 N=24 Effects of PRK 124 Lotion in Acne Rosacea
Acne Rosacea
Primary: Erythema Severity — 44.53 Erythema percent improvement
N/A N=22 Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale
Phase 4 N=207 Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
Papulopustular Rosacea
Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward) — -10.5; -9.4…
Phase 2 N=24 Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
Papulopustular Rosacea
Primary: Change From Baseline in Papule/Pustule Count at Week 16 — -5.00 papules and pustules — p=0.01
Phase 4 N=30 Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
Erythematotelangiectatic Rosacea
Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale
Phase 3 N=372 A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
Papulopustular Rosacea
Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 50.1; 25.9 Percentage of Participants
Phase 3 N=361 A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
Papulopustular Rosacea
Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 43.5; 16.1 Percentage of Participants
Phase 3 N=552 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea
Rosacea
Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants
Phase 3 N=486 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
Rosacea
Primary: Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count — 65.47; 67.89; 55.51 percentage of lesion reduction
Phase 3 N=330 A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
Papulopustular Rosacea
Primary: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. — 74; 22 Participants
Phase 4 N=170 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
Rosacea
Primary: Change From Baseline in Inflammatory Lesion Counts — -4.3; -3.2 inflammatory lesions
N/A N=10 Combination Gel and Vascular ND in Mild to Moderate Rosacea
Rosacea
Primary: IGA of Improvement — 3.1; 3.5 units on a scale
Phase 3 N=961 Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
Papulopustular Rosacea
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) — 32.1…
Phase 2 N=401 Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Papulopustular Rosacea
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) — 43.4…
Phase 3 N=323 A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
Papulopustular Rosacea
Primary: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. — 79; 25 Participants
Phase 2 N=83 Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
Papulopustular Rosacea
Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Study (LOCF: Last Observation Carried Forward)…
Phase 3 N=50 An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Rosacea · Erythema
Primary: Responder — 16.7 percentage of responders
Phase 3 N=504 A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
Papulopustular Rosacea
Primary: Absolute Change From Baseline in Inflammatory Lesion Count at Week 40 — 23.0; 22.5 Lesions
Phase 3 N=92 Patient-Reported Outcome Of Facial Erythema (PROOF)
Rosacea · Erythema
Primary: Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment — 69.6; 40.4 Percentage of participants — p== 0.0065
Phase 4 N=273 Oracea Soolantra Association in Participants With Severe Rosacea
Rosacea
Primary: Percent Change From Baseline in Inflammatory Lesion Count at Week 12 — -80.29; -73.56 percent change — p=0.032
Phase 3 N=771 A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
Facial Papulopustular Rosacea
Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 18.38; 14.53 Lesions — p=<0.0001
Phase 3 N=751 A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
Facial Papulopustular Rosacea
Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 17.56; 15.34 Lesions — p=0.0031
Phase 2 N=34 Effect of CD07805/47 Gel in Rosacea Flushing
Rosacea
Primary: Total Number of Flushes for Each 2-week Period — 15.3; 16.3 Flushes count — p=0.7420
Phase 2 N=20 Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit